Recordati S.p.a. · MIL:REC
Recordati — Goldman Sachs Twenty Seventh Annual Global Healthcare Conference (June 2006)
8 slides from Recordati's conference presentation, Jun 13, 2006
Slide 1: Goldman Sachs Twenty Seventh Annual Global Healthcare Conference
Goldman Sachs Twenty Seventh Annual Global Healthcare Conference Dana Point, California, 13 June 2006 2006 - 2010
Slide 2: Company profile
Company profile • A fully integrated pharmaceutical company listed on the Italian Stock Exchange since 1984 • Original research focused on cardiovascular and urological fields • Marketing operations in all the main European countries (France, Germany, Italy, Spain, UK) covering a broad range of ther
Slide 3: Breakdown of 1Q 2006 pharmaceutical revenue
Breakdown of 1Q 2006 pharmaceutical revenue (€ 153m) UK Spain International licensees 2% Germany 7% 19% 8% % of pharmaceutical revenue Zanidip® (lercanidipine) 29% France Peptazol® /Ulcotenal® 9% 23% Italy (pantoprazole) 41% Elopram® /Entact® 8% (citalopram/escitalopram) Hexa line (biclotimol) 4% Li
Slide 4: Zanidip (lercanidipine) - % share of CCB market
ZANIDIP® (lercanidipine) • Latest generation calcium-channel blocker. Lercanidipine as a % of all Lipophilic dihydropyridine. calcium channel blockers • Natural once a day. Potent, long-lasting Bubble size represents $ market value of CCB’s vasodilatory activity. Highly vasoselective with gradual on
Slide 5: R&D pipeline
R&D pipeline PHASE II FILED FOR NAME ORIGINATOR INDICATION DISCOVERY PRE CLINICAL PHASE I PoC PHASE III APPROVAL Project S Recordati Chronic Heart Failure (CHF) 3 new projects Recordati Overactive bladder and Incontinence REC 0035 Recordati Benign prostatic hyperplasia REC 0765 REC 0206 Recordati Ov
Slide 6: Outlook for 2006 and 2010 targets
Outlook for 2006 and 2010 targets (million euro) 2005 2006 REVENUE 576.1 >600 OPERATING INCOME 111.1 >120 NET INCOME 64.5 >75 Assumptions: Not considering any future acquisitions (million euro) 2005 2010 CAGR REVENUE 576.1 1,000 12% OPERATING INCOME 111.1 >200 >12.5% NET INCOME 64.5 >120 >13% Assump
Slide 7: 2010 revenue target
2010 revenue target Revenue • in Priority to reinforce key EU markets 2010 current geographic coverage in • Entry into additional European markets • Sales of corporate products to increase proportionally over local products • Continued attention to the life cycle management of lercanidipine (million
Slide 8: Safe harbour and company profile
Safe harbour and company profile Statements contained in this presentation, other than historical facts, are “forward- “forward-looking statements” (as such term is defined in the Private Securities Litigation Reform Act of 1995). 1995). These statements are based on currently available information,
Recordati — Goldman Sachs Twenty Seventh Annual Global Healthcare Conference (June 2006) on 6ix